Synopsys (SNPS) Cash & Equivalents (2009 - 2026)

Synopsys has reported Cash & Equivalents for 18 years, with the latest figure at $43.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 98.82% year-over-year to $43.1 million; the trailing twelve-month figure through Jan 2026 stood at $43.1 million (down 98.82% YoY), and the FY2025 full-year result was $2.9 billion, down 25.92% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $43.1 million, down from $2.9 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $14.1 billion in Q2 2025, with the low at $43.1 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $2.5 billion across 5 years, with a median of $1.6 billion in 2022.
• Annual changes were most pronounced in 2025 — Cash & Equivalents soared 838.02% — and 2026, when it plunged 98.82%.
• Synopsys' Cash & Equivalents stood at $1.4 billion in 2022, then rose by 11.67% to $1.6 billion in 2023, then jumped by 145.88% to $3.9 billion in 2024, then decreased by 25.92% to $2.9 billion in 2025, then slumped by 98.51% to $43.1 million in 2026.
• The last three Cash & Equivalents figures came in at $43.1 million (Q1 2026), $2.9 billion (Q4 2025), and $2.6 billion (Q3 2025), per Business Quant data.